BIOTON
Research BIOTON (BIO.WA) on Bullrun: market cap PLN 326.28M, P/E 76.0. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerBIO.WA
- ExchangeXWAR
- CountryPoland
- SectorHealthcare
- IndustryBiotechnology
- CurrencyPLN
- Market capPLN 326.28M
- P/E76.0
- Financial periodQ1 2026
- RevenuePLN 49.12M
- Net income-PLN 5.15M
- Free cash flow-PLN 2.22M
- Gross margin29.5%
Valuation Snapshot
latest market cap is PLN 326.28M; P/E is 76.0.
Peer valuation comparison
Latest P/E is 76x versus a Healthcare sector median of 23.44x (224.3% above).
Latest P/E is 76x versus a Poland median of 12.57x (504.7% above).
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-09-05 | PLN 326.28M | 76.0 | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 PLN.
About BIOTON
BIOTON S.A., a biotechnology company, develops, manufactures, markets, and sells pharmaceutical ingredient and medicinal products in Poland and internationally. The company offers recombinant human insulin; and oral diabetic drugs.BIOTON S.A. was founded in 1989 and is based in Ozarów Mazowiecki, Poland.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is BIOTON's market cap?
BIOTON's market capitalization is PLN 326.28M.
What is BIOTON's P/E ratio?
BIOTON's price-to-earnings (P/E) ratio is 76.0.
What does BIOTON do?
BIOTON S.A., a biotechnology company, develops, manufactures, markets, and sells pharmaceutical ingredient and medicinal products in Poland and internationally. The company offers recombinant human insulin; and oral diabetic drugs.BIOTON S.A. was founded in 1989 and is based in Ozarów Mazowiecki, Poland.